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Albumin displays several important functions for homeostasis amongst which the maintenance of the
plasma redox-state. The study aim was to compare the redox state of pharmaceutical human albumin
preparations since it reﬂects the oxidation-reduction status of the surrounding environment. Using an
array of analytical methods, four commercially available albumins were compared with respect to their
structural characteristics (cobalt ion binding, glycation, spectrophotometric and ﬂuorometric proﬁles)
and their ability to scavenge hydroxyl, peroxyl or free radicals. The different albumins exhibited a similar
structural proﬁle as well as hydroxyl and peroxyl scavenging activities. By contrast, the albumin from LFB
(Vialebex®) possessed a signiﬁcantly higher capacity to transfer electrons to DPPH, as compared with
other albumins that was correlated with the level of free cysteine-34.
Commercially available albumins differed for some of their antioxidant properties. The albumin
preparation possessing the highest level of free cysteine-34 exhibited the highest antioxidant potential.
© 2016 LFB Biotechnologies. Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Free radicals are highly reactive molecules produced as the
result of normal cellular oxygen metabolism in mammals. At low or
moderate levels free radicals exert beneﬁcial effects on cellular
responses and immune function whereas at high concentrations,
they generate oxidative stress, a deleterious process that can
damage all cell structures and cause the onset and/or progression of
a growing number of diseases [1e3].
The pivotal role of oxidative stress in pathophysiology, which is
elicited by a redox imbalance between free radicals and antioxi-
dants, forms the rationale for antioxidant therapeutic approaches
[2e5].
Plasma, a body compartment known to be exposed to contin-
uous oxidative stress, contains a wide range of endogenous anti-
oxidant species among which albumin represents the most
abundant and important [6,7]. Therefore, human serum albumin
(HSA) used as a resuscitation ﬂuid could represent an opportunityTherapeutique, Laboratoire
es, Parc Eurasante, 84, rue du
53 30 41.
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.0/).to enhance endogenous antioxidant protection in critical patho-
logical interventions [8]. HSA infusion has been shown to allow for
restoring thiol-radical deﬁcient stock during cirrhosis and
improving thiol-dependent anti-oxidant protection [9]. In the same
way a beneﬁcial effect of HSA administration in patients with acute
respiratory distress syndrome was evidenced by the resulting
enhancement in plasma thiol-dependent antioxidant status and in
the reduction in protein oxidative damage [10]. Kremer et al.
showed a protective dose-dependent effect of HSA treatment both
on mice survival and endothelial dysfunction by inhibiting in-
ﬂammatory and oxidative stress pathways induced by endotoxins
[11]. Most of the antioxidant properties of albumin can be attrib-
uted to its unique biochemical structure [8]. HSA contains 35
cysteine residues of which 34 are involved in intramolecular di-
sulﬁde bonds thus contributing to overall tertiary structure. One
free cysteine residue, Cys-34, is the major extracellular source of
redox active thiol group (-SH) which accounts forz 80% of thiols in
plasma [7,9]. The thiol moiety of Cys-34 is reactive and is a potent
scavenger of reactive oxygen and nitrogen species (ROS/RNS) sup-
porting an important redox regulator role in extracellular
compartment [7,12]. Another part of the antioxidant properties of
HSA is due to its ligand-binding capacities. The N-terminal part of
HSA (N-Asp-Ala-His-Lys) forms a high afﬁnity site for Cu2þ, Ni2þal Alliance for Biological Standardization. This is an open access article under the CC
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limits the potential of cationic metal ions to generate reactive ox-
ygen species (ROS) after a reaction with oxygen and, consequently,
to damage other biomolecules. Furthermore, an indirect antioxi-
dant activity of HSA results from its ability to transport bilirubin
whereby the albumin-bilirubin complex was shown to act as an
inhibitor of lipid peroxidation [14].
Serum albumin is heterogeneous with respect to its reduced
thiol content, reported as typically 0.6e0.7 SH/HSA [15,16]. Bio-
process and storage conditions increase heterogeneity of HSA
which was shown to be more pronounced in commercially avail-
able preparations intended for clinical use [17e22]. Awide range of
variable post-translational modiﬁcations has been reported in
commercially available HSA preparations including glycation,
missing terminal amino-acids and cysteinylation and nitrosylation
of the free cysteine residue [18,20,22]. This variability may add to
the controversy surrounding the administration of albumin and
contributes to the conﬂicting evidence from clinical trials [23]. The
administration of commercially available HSA that is largely
oxidized might augment the oxidative stress burden on an already
oxidatively-challenged critically ill patient [19].
The aim of this study was to analyze several commercially
available albumin preparations to assess their antioxidant capacity
and, more precisely, the relationship between the antioxidant
ability and the level of reduced Cys-34 residues. For this purpose
the antioxidant proﬁles of these therapeutic HSA preparations were
compared using an array of antioxidant assays.
2. Materials and methods
2.1. Chemicals
All chemicals were purchased from SigmaeAldrich (L'Isle
d’Abeau, France), VWR (Fontenay sous Bois, France) and Merck
(Fontenay sous Bois, France) unless otherwise noted.
Human glycated albumin (GA) ELISA kit (ref. EO997h) was
purchased from EIAab (Wuhan, China).
DTNB (5,50-dithiobis-(2-nitrobenzoic acid) or Ellman's reagent
(ref. 22582) was purchased from Pierce (Rockford, USA).
DPPH (2,2-diphenyl-1-picrylhydrazyl) was purchased from
Merck Millipore (Darmstadt, Germany).
The ORAC (Oxygen Radical Absorbance Capacity) antioxidant
assay kit was purchased from Zen-Bio, Inc (Research Triangle Park,
USA).
2.2. Albumin samples
A panel of several commercially available albumin preparations
from different suppliers were tested and compared: 3 lots of
“Albumine Humaine 20%” from Baxter (Mississauga, Canada); 3 lots
of Albuminar or AlbuRx 25%from CSL-Behring (Victoria, Australia);
3 lots of Albunorm 20% from Octapharma (Lachen, Switzerland)
and 3 lots of Vialebex® and Ydralbum® from LFB, (Les Ulis, France).
The batches were randomly purchased. All the storage buffers
contained caprylic acid and sodium chloride. N-Acetyl-tryptophan
was also present except to the two products from LFB. All the
products were stored as recommended by the manufacturers and
used at least 6 months before their expiration dates, except to 1 lot
from Baxter at 1 month before. One batch of Vialebex out-of-date
was systematically used as reference without demonstrating any
difference in the results with the fresh batches (data not shown).
Data from this batch were however not aggregated. The albumin
preparations (2 mg) were analyzed by 10% SDS- PAGE. The electro-
phoretic proﬁles were similar between the different preparations
with a purity degree >98% (data not shown).2.3. Evaluation of the structural quality of human albumin
preparations
2.3.1. Albumin binding cobalt assay
The albumin samples were assessed for cobalt binding using a
colorimetric assay as described by Bar-Or et al. [24]. Brieﬂy, 50 mL of
a solution of 0.1% cobalt chloride in H2O2 was added to 200 mL of a
serial albumin dilutions (0e60 mg/mL), gently mixed and then
incubated for 10 min to allow for cobalt-albumin binding. Dithio-
threitol (DTT, 1.5 mg/mL in H2O, 50 mL) was then added as a
colorizing agent and the reaction was quenched 2 min later by
adding 1.0 mL of 0.9% NaCl solution. The color development pro-
duced by DTT was read at 470 nm using a spectrophotometer
(Inﬁnite M200 Pro TECAN). The albumin-cobalt without DTT was
used as blank and the results were reported in optical density units
(ODU) as a function of albumin concentration.
2.3.2. Evaluation of albumin glycation
A commercial enzyme-linked immunosorbent assay (ELISA) was
used to evaluate the glycation level in human albumin prepara-
tions. Each albumin sample (100 mL), diluted in provided sample
buffer, to a range of concentrations from 0.0016 to 0.1 mg/mL was
directly transferred into a 96-well plate and subsequently incu-
bated for 1 h at 37 C. After a 4-washing step using provided
washing buffer (the washing step was repeated after each incuba-
tion), wells were saturated using a provided 2% Tween-20 solution
for 1 h at 37 C. The anti-advanced glycated end-products (AGE)
antibody (100 mL of 1 mg/mL solution) was added and incubated
overnight at 4 C. Antibody binding was detected using horseradish
peroxidase (HRP)-coupled anti-rabbit IgG (100 mL, 0.04 mg/mL) and
developed using 0-Phenylenediamine (OPD, 0.8 mg/mL in citrate
buffer). The reaction was then stopped by addition of H2SO4 2.5 M
(50 mL) and the optical density was determined using a microplate
reader set at 492 nm. A glycated albumin from SigmaeAldrich
containing 2 hexoses/molecule was used as control.
2.3.3. UV/visible and ﬂuorescence spectrometry of albumins
Albumins were diluted extemporaneously with phosphate-
buffered saline (PBS) before the measurement. The UV/visible
spectra were obtained by scanning the albumin samples (200 mg/
mL) in the wavelength range of 230e600 nm using the Inﬁnite®
M200 PRO spectrophotometer (TECAN).
Fluorescence emission measurements were performed using
the same spectroﬂuorometer. The excitation was set at 295 nm and
the emission was collected in the range of 325e600 nm. Different
concentrations of albumin solutions (12.5, 25 and 50 mg/mL) were
analyzed.
2.4. Evaluation of the antioxidant capacity of human albumin
preparations
2.4.1. Albumin controls
A reduced albumin solution, or positive control, was prepared as
follows: Albumin solution (Vialebex®; 200 mg/mL or 3 mM) was
dialyzed against a degassed phosphate buffer 0.1M, 0.3 M NaCl, pH
6.86. A 0.1% DTT solution was extemporaneously prepared and
incubated with dialyzed albumin for 45 min at room temperature
in a w/w ratio 5:1. The resulting solution was then extensively
dialyzed against CH3COONa 0.1M, pH 5.5 and stored at 80 C.
An oxidized albumin solution, or negative control, was also
prepared. Albumin (Vialebex®; 200 mg/mL) was dialyzed against
PBS. A 12.5 mg/mL N-ethylmaleimide (NEM) solution (0.1M) was
prepared and incubated for 60 min at 35 C in a ratio of 200 mg
albumin for 1.25 mg NEM. The solution was then extensively
Fig. 1. Cobalt-binding capacity of commercial albumins. Each value is the average
(±SD) of triplicate experiments performed for each lot.
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after dilution in the reaction buffer.
2.4.2. ORAC test
The ORAC (Oxygen Radical Absorbance Capacity) assay mea-
sures a ﬂuorescent signal from a probe that decreases in presence
of a ROS generator. Addition of an antioxidant absorbs the
generated ROS and allows for the ﬂuorescent signal to persist [25].
The ORAC assay is unique in that its ROS generator, AAPH (2,2’-
azobis(2-methylpropionamidine) dihydrochloride), produces a
free peroxyl radical upon thermal decomposition. This free radical
is commonly found in the body making this reaction biologically
relevant [25,26]. The ORAC antioxidant assay was performed
following the manufacturer's instructions. The reaction was car-
ried out into thewells of a microtiter plate containing each sample
to be tested (25 mL of albumin or standard) and a ﬂuorescein so-
lution diluted as recommended by the manufacturer. After adding
25 mL of AAPH in each well the ﬂuorescence was recorded every
minute for 30 min using the Inﬁnite® M200 Pro spectroﬂuoro-
metric analyzer (excitation 485 nm; emission 538 nm). Areas
under the ﬂuorescence decay curve (AUC) were automatically
calculated using the Magellan software (Tecan, France). The con-
centration of antioxidant in the test sample is proportional to the
ﬂuorescence intensity and was assessed by comparing the net
area under the curve (difference between the AUCs corresponding
to the sample with antioxidant and the sample without antioxi-
dant, respectively) to that of 6-Hydroxy-2,5,7,8-tetramethyl-
chroman-2-carboxylic acid (Trolox) used as calibration standards
(6.25e100 mM). Results were expressed as a function of mM of
Trolox equivalent/mM of antioxidant by using Trolox calibration
standards.
2.4.3. Quantiﬁcation of free thiols using Ellman's reagent
Brieﬂy, a stock solution of 5,5'-dithiobis-(2-nitrobenzoic acid)
(DTNB) at 2 mg/mL in 100 mM phosphate buffer, 1 mM EDTA, pH
8.0 was prepared. Each albumin test sample (190 mL) diluted in PBS
(concentrations ranging from 0.0125 to 0.1 mM) was added to a
DTNB solution (10 mL). The reaction was allowed to proceed for
15 min at room temperature and the ﬁnal absorbance was
measured at 412 nm. A calibration curve was performed by
sequential dilutions of a 100 mM DL-cysteine hydrochloride hydrate
stock solution in PBS over a concentration range from 0.005 to
0.25 mM. Results were expressed as the number of free-cysteine
residues per mole of albumin.
2.4.4. Hydroxyl scavenging capacity of human albumin
In this assay, the chromogen TMB (3,30,5,50 Tetramethylbenzi-
dine) yields a blue color when oxidized by hydroxyl radicals pro-
duced by the Fenton's reaction; conversely the oxidized TMB is
reduced to a colorless compound by antioxidants. TMB solution
(20 mL at 5mg/mL) was loaded into a 96-well microplate, then 20 mL
of Trolox (ranging from 0 to 1 mM) or albumin (from 0.25 to 1 mM)
solutions were added, followed by the addition of 20 mL of Fenton
reagent.
The reaction was allowed to proceed for 20 min at room tem-
perature. An acetic acid solution (200 mL at 10%) was added to
neutralize the reaction and the absorbance was measured at
452 nm. Hydroxyl scavenging activity was calculated as follows:
(1-Asample/Acontrol)  100
Asample is the absorbance of albumin or Trolox sample
Acontrol is the absorbance of the negative control (reaction buffer)2.4.5. Free radical-scavenging capacity of human albumin
Total free radical-scavenging capacities of albumin preparations
were measured using the DPPH assay method based on the
reduction of the stable free radical DPPH. When a solution of DPPH
is mixed with a substance acting as a hydrogen atom donor, a
reduced form of DPPH, DPPH-H, is obtained with simultaneous
decrease in absorbance at 517 nm [27].
Brieﬂy, 400 mL of albumin preparation (0.2 mM) was mixed with
400 mL of DPPH solution (0.5 mM in ethanol) and incubated for
25 min at room temperature. The solution was vortexed periodi-
cally and then centrifuged for 5 min at 10,000 g. The absorbance of
the supernatant (A) was measured at 517 nm against ethanol as
blank using a biophotometer (Eppendorf BioPhotometer). The
inhibitory percentage of DPPH corresponding to the DPPH free
radical scavenging activity was calculated according to the
following equation:
DPPH scavenge (%)¼ (AcontrolAsample)/Acontrol 100
Asample is the absorbance of the mixture containing albumin and
DPPH
Acontrol is the absorbance of the negative control consisting of a
mixture of acetate buffer and DPPH (v/v)
3. Results
3.1. Structure quality of human albumin preparations
Prior to evaluation of antioxidant capacities of various thera-
peutic albumin preparations, the integrity of the structure was
assessed as a relationship between the conformation and the ac-
tivity of albumin.
3.1.1. Evaluation of the cobalt binding capacity
In normal human albumin, the N-terminal region comprises the
amino-acid sequence N-Asp-Ala-His-Lys which has high ability to
bind metallic ions such as cobalt [28]. However, structural analysis
by mass spectrometry showed a truncation of the N-terminal part
of commercial HSA products [29].
Different commercially available lots of albuminwere compared
for their ability to bind cobalt ions. Increasing concentrations of
albumin samples were incubated with a constant amount of Co2þ
ions. As shown in Fig. 1, albumin preparations bind Co2þ ions in a
dose-dependent manner. In addition, the behavior of all albumins
Fig. 3. Spectrophotometric analysis of different albumin preparations. Each value
is the average (±SD) of triplicate experiments performed on 3 batches of each tested
albumin.
Fig. 4. Fluorometric analysis of different albumin preparations.
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overlay of the absorbance proﬁles.
3.1.2. Evaluation of glycated albumin
The data in Fig. 2 clearly shows that the levels of AGE-albumin
were similar in all albumin preparations from various suppliers.
Furthermore, the glycation level of these preparations was slightly
lower than that of the control which amounted to 2 mol of hexose
per mole of albumin.
3.1.3. Spectrometric and ﬂuorometric analysis of albumins
The spectrophotometric absorbance of different albumin prep-
arations was scanned between 230 and 600 nm. As shown in Fig. 3,
a common spectrum was evidenced for all products comprising a
single narrow absorption peak at around 300 nm followed by a
shoulder at 400e410 nm. It was to be noted that the albumins from
LFB (Vialebex® and Ydralbum®) exhibited a high batch-to-batch
consistency with superimposable absorption proﬁles which was
not the case for all the products (Fig. 3). Intensity of the shoulder
between 400 and 410 nm differed, however, from one albumin to
another, suggesting the presence of contaminants in various
amounts.
Fluorometric analysis of the albumin samples conﬁrmed the
homogeneous composition of the different albumin preparations. It
has to be noticed that the spectra were not smooth, in particular for
albumins from Octapharma, CSL-Behring and Baxter for which a
shoulder emission region appeared at 400e410 nm (Fig. 4).
3.2. Evaluation of the antioxidant capacity of human albumin
preparations
3.2.1. Thiol quantiﬁcation using Ellman's reagent
To measure the content of free cysteine residues available, Ell-
man's reagent was used. Fig. 5a reports free cysteine levels in the
different albumin preparations. The level of free cysteine residues
ranged from 0.02 to 0.43 per mole of albumin. As expected DTT and
NEM treatments signiﬁcantly affected the levels of available cys-
teines. NEM blocked almost totally the free cysteine residues
whereas a mild treatment by DTT maintained the level of free
cysteines very close to 1.
To assess whether or not the differences observed between the
different lots of albumin were statistically signiﬁcant all individual
data were aggregated and presented in Fig. 5b. A paired t-test wasFig. 2. Comparison of albumin from LFB (Vialebex®), Octapharma, Baxter and CSL-
Behring albumins using an anti-AGE antibody. Each value is the average (± SD) of
duplicate experiments performed for each lot.applied and the p value was reported. The albumin from LFB
(Vialebex®) was found to have a signiﬁcantly higher amount of free
cysteines as compared with the other compounds. Albumin prep-
arations ranked as follows: albumin from LFB
(Vialebex®) > albumin from LFB (Ydralbum®) > albumin from
Octapharma > albumin from CSL-Behring > albumin from Baxter.3.2.2. ORAC assay
Different concentrations of oxidized, reduced and native albu-
min from LFB (Vialebex®) (0e1000 mg/mL) were compared to a
standard curve of Trolox for their ability to protect ﬂuorescein from
oxidation by ROS generated by AAPH (Fig. 6). Results showed that
the antioxidant potential of the oxidized, reduced and native al-
bumin from LFB (Vialebex®) is nearly equivalent. This observation
strongly suggests that the peroxyl scavenging activity of HSA is not
only due to SH free groups of Cys-34 but that other reactive groups
are involved in this antioxidant activity.
Dialyzed albumin preparations were then compared for their
antioxidant capacities. Results showed that the oxidant capacity
was not signiﬁcantly different between the albumin preparations
tested (Fig. 7).3.2.3. Hydroxyl scavenging capacity of human albumin
Hydroxyl radical scavenging capacity of HSA was determined
using the chromogen TMB.
Fig. 5. a. Number of free cysteine residues per mole of albumin. The values arose
from a triplicate measurement of at least four different concentrations of albumin. b.
Comparison of the average levels of free cysteine residues from various albumins.
Individual values collected from all the assays performed were aggregated. The average
values are represented by a horizontal line.
Fig. 6. Antioxidant effects of native, reduced and oxidized albumins from LFB (Viale-
bex®, DTT- Vialebex® and NEM- Vialebex®) in ORAC assay.
Fig. 7. Trolox equivalent from dialyzed commercial albumins. Each value is the
average (±SD) of duplicate experiments performed on 1 to 3 batches of each tested
albumin.
Fig. 8. Comparison between DTT-treated, NEM-treated and native forms of the
albumin from LFB (Vialebex®) protective activity. The values arose from a triplicate
measurement of at least four different concentrations of albumin.
Fig. 9. Protective capacity of different albumin preparations. Each concentration
was assayed in triplicate in 2 assays performed on 3 lots of each tested albumin.
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highest antioxidant capacity as compared to the NEM-oxidized
albumin. Native form of the albumin from LFB (Vialebex®)
showed an intermediate proﬁle between the two controls (Fig. 8).These data showed that hydroxyl protective activity of the al-
bumin from LFB (Vialebex®) preparation was mediated in part by
the free cysteine-34 since chemical treatments of this residue were
able to reinforce or diminish the protective activity of the albumin
from LFB (Vialebex®). These data also revealed that the assay
measuring the protection of TMB by albumin can be used to
discriminate between albumins with various antioxidant
properties.
The hydroxyl scavenging capacity was assayed in the different
albumin preparations (Fig. 9).
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lesser extent from CSL-Behring exhibited a batch-to-batch vari-
ability when compared to the other products as regards their
scavenging activity. Albumins from Octapharma and Baxter
showed the highest and the lowest antioxidant capacities against
hydroxyl radicals, respectively, as compared with the other prod-
ucts. This difference decreased for high albumin concentrations of
1 mM.3.2.4. Free radical-scavenging capacity of human albumin
preparations
The ability of several commercial albumins to scavenge the free
radical of DPPH was assessed using dialyzed albumin in acetate
buffer. As for the preliminary assay, albumins tested were
compared to reduced and oxidized forms of the albumin from LFB
(Vialebex®). A signiﬁcantly decreased capacity of oxidized formwas
evidenced as compared with reduced form (Fig. 10a). However, this
antioxidant activity was partially mediated by the Cys-34 since the
total oxidation of this residue by NEM did not totally abrogate this
scavenging activity.
Amongst all albumin preparations tested, the albumin from LFB
(Vialebex®) displayed the higher antioxidant potential. This latter
was recovered at a very similar level from several independent
batches of the albumin from LFB (Vialebex®). To assess whether orFig. 10. a. Comparison of DPPH protecting ability of several commercial albumins.
Each value is the average (± SD) of triplicate experiments. b. Comparison of DPPH
protecting ability of several commercial albumins. Individual values collected from
all the assays performed were aggregated. The average values are represented by a
horizontal line.not the differences observed between the different lots of albumin
were statistically signiﬁcant, all individual data were aggregated
and presented in Fig. 10b. A paired t-test was applied and the p
value was reported. Results conﬁrmed that Vialebex® has a signif-
icantly higher antioxidant potential compared to the other albu-
mins tested indicating that the albumin from LFB (Vialebex®) has
the highest capacity in transferring electrons to DPPH. Scavenging
activity expressed as percentage of DPPH inhibition was correlated
with free cysteine level as shown in Fig. 11. As expected DPPH in-
hibition increases with free cysteine level.4. Discussion
Albumin preparations intended for clinical use derive from
fractionation of collected and pooled human plasmas using ethanol
precipitation and chromatography puriﬁcation procedures. In so-
lution, HSA may exist in various forms such as monomers, oligo-
mers or polymers [31]. Since albumin has a natural tendency for
aggregation and/or conformational changes under environmental
conditions such as those encountered during albumin preparation
processes, it can rapidly lose its native conformation [32]. Hetero-
geneity may also increase during puriﬁcation processes in vitro,
including isolation, concentration and storage [33]. Despite the fact
that all products fulﬁlled the quality requirements established in
the European Pharmacopoeia, commercial HSA preparations are
known to be heterogeneous, in particular with respect to the redox
status of the Cys-34. For instance, Bar-Or et al. found signiﬁcant
variability in albumins, even in lots from the same manufacturer
when investigating the heterogeneity and oxidation status of a
number of commercial albumins. The level of reduced thiol at Cys-
34 was much lower in commercial products (up to ~45%) compared
with albumin freshly puriﬁed from healthy volunteers (~75%) [19].
Therefore, it appears important to evaluate the quality of albumin
preparations. In the present study, different analytical methods
were used aiming at evaluating the structural integrity of com-
mercial HSA products as well as their antioxidant capacity.
The structural integrity of human albumin preparations was
assessed through the cobalt binding assay, measurement of gly-
cated albumin and analysis of spectrophotometric and ﬂuorometric
spectra.
Cobalt binding assay is based on albumin ability to exhibit sites
for a number of metal cations including copper, nickel, calcium,
magnesium, zinc, cadmium, mercury, aluminum, manganese and
cobalt [12].
Cobalt binding occurs at three distinct sites in HSA with
different afﬁnities and speciﬁcities [34].
In the present study the different commercially available albu-
min preparations showed a similar cobalt-binding ability suggest-
ing that all the overall cobalt binding regions were identically
preserved within the various products. The potential of albumins toFig. 11. Scavenging activity as a function of free cysteine.
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would thus be equivalent in all the products analyzed.
Glycation is a general spontaneous process occurring in vivo in
proteins which has signiﬁcant impact on their physical and func-
tional properties. During this process hexose residues form adducts
with albumin resulting in AGEs. AGEs accumulate naturally as a
result of aging but the process can be accelerated under conditions
of hyperglycemia and oxidative stress [35]. Indeed glycation might
disrupt molecular conformation, altering enzymatic activity and
interfering with receptor functioning [30]. Serum albumin is highly
sensitive to glycation because of its lifetime as well as its high
concentration in blood circulation [36]. In healthy persons or blood
donors the proportion of glycated albumin is in the range of 1e10%
[12]. Numerous studies have permitted the identiﬁcation of up to
29 sites that can be glycated in HSA in vivo [37]. The glycation level
of the different albumin preparations tested was lower than that
observed for the positive control which was glycated with an
average of 2 mol of hexose per mole of albumin. Furthermore, no
variation in AGE derivatives of HSAwas observed between products
from different suppliers. This was expected since the glycation level
characterizes the properties of the starting material used to pro-
duce HSA rather than the production process.
Spectrometric and ﬂuorometric analyses showed a homoge-
neous composition of the different albumin preparations. Never-
theless, the spectra of albumin samples from CSL-Behring and
Octapharma exhibited a pronounced shoulder in the region be-
tween 400 and 410 nm, suggesting the presence of additional
proteins. This absorption shoulder was also observed through the
ﬂuorometric analysis and probably corresponds to the presence of
bilirubin that is known to bind albumin and that is detected at this
wavelength [38].
It is well documented that the different methods used for serum
albumin preparations have an impact on purity and yield. Depend-
ing on the fractionation process applied, i.e. chromatographic- or
ethanol-based, levels of bilirubin may differ from one albumin to
another [38]. It is noteworthy that although some studies hypoth-
esized that the residual levels of albumin-bound bilirubin may help
protect albumin from oxidation during the pasteurization step [39],
free bilirubin has undesirable toxic effects [40,41].
To benchmark the antioxidant properties of different commer-
cial albumin preparations an array of analytical methods was used.
The ORAC assay measures the peroxyl radical scavenging of sam-
ples [42]. Results showed that human albumin possessed a peroxyl
scavenging activity, as compared with the standard Trolox, which
was independent of the redox state of cysteine residues since the
two controls, oxidized and reduced forms of albumins could not be
distinguished. These results are in agreement with Okazaki et al.
[18] who showed that peroxyl scavenging activity of albumin was
independent of cysteine residues and suggested that methionine
moieties are involved in this activity. Measurement of free cysteine
content using Ellman's reagent was performed on the different
commercial albumins tested and compared with the free cysteine
content of DTT-reduced or NEM-oxidized albumin controls. Results
showed that a 2.5-fold differential was observed between the
highest (0.43/molecule) and the lowest (0.18/molecule) free
cysteine ratio. Amongst tested albumins, the albumins from LFB
(Vialebex® and Ydralbum®) showed the highest levels of free
cysteine residues with ratios of 0.43/molecule and 0.39/molecule,
respectively. The reducing potential of the same lots of albumins
was assessed using TMB, a chemical compound serving as recipient
for electron transfer from albumin and the Fenton reagent as a
source of hydroxyl radicals. Results showed that protection of TMB
by an antioxidant was able to distinguish two albumin controls,
DTT-reduced and NEM-oxidized Vialebex®, demonstrating that the
scavenging activity was mediated by the free cysteine-34.The albumins from Octapharma (Albunorm®) and LFB (Viale-
bex® and Ydralbum®) showed a good batch-to-batch consistency
associated with a better antioxidant potential which was not the
case for all the other providers. The reducing potential of the same
lots of commercial albumins was assessed using DPPH as a reactive
hydrogen acceptor. This compound is widely used to evaluate the
antioxidant activity of natural products [43,44]. Results showed
that the albumin from LFB (Vialebex®) exhibited a signiﬁcantly
higher capacity in transferring electrons to DPPH as compared with
the other albumins. This was correlated with the levels of free
cysteine-34. These results are consistent with the study by Kawa-
kami et al. who showed that oxidized HSA has reduced scavenging
ability against hydroxyl radicals [45]. It was found that the degree
of hydroxyl radical scavenging activity of HSAwas highly correlated
with its reduction status. It is noteworthy that the formulation
buffer of the albumin from LFB (Vialebex®) is free of N-acetyl
tryptophan, an agent used to protect the sulfhydryl group of HSA
against oxidation, as opposed to the other albumin preparations
[46]. The results presented in this paper suggest that the presence
of such adjuvant in albumin preparations do not help in main-
taining a high level of reduced cysteine residues.
5. Conclusion
As already stated by Turell et al. the pharmacological and clinical
consequences of the alteration of the redox state of pharmaceutical
HSA preparations, particularly the abundance of irreversibly
oxidized isoforms, should be further explored and taken into
consideration [47]. Kawakami et al. [45] and Mera et al. [48]
showed that structural changes of HSA caused by oxidative modi-
ﬁcation on the thiol moiety of Cys-34 affected the drug-binding
properties of this protein, altering steady-state plasma concentra-
tion of drugs which was correlated with monitoring efﬁcacy and
adverse effects. Thus, it is now important to determine whether the
differences in antioxidant properties observed may have a signiﬁ-
cant impact on therapeutic albumin functions.
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